Clinical trial
Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.
NCT00422955 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00422955 |
|---|---|
| Title | Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy. |
| Official title | A 16-week, Randomised, Double-blind, Placebo-controlled, Single-centre Study to Investigate Fluid Retention in Insulin-treated Subjects With Type 2 Diabetes Mellitus and Varying Degrees of Autonomic Neuropathy When Administered Rosiglitazone 4mg Twice Daily |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Neuropathy, Diabetic |
| Intervention type | Drug |
| Interventions | rosiglitazone |
| Enrollment | 36 |
| Start date | Nov 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jan 17, 2007 |
| Last update posted | Sep 15, 2016 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: